#BEGIN_DRUGCARD DB02442

# AHFS_Codes:
Not Available

# ATC_Codes:
Not Available

# Absorption:
Not Available

# Biotransformation:
Not Available

# Brand_Mixtures:
Not Available

# Brand_Names:
Not Available

# CAS_Registry_Number:
Not Available

# ChEBI_ID:
Not Available

# Chemical_Formula:
C3H6NO4Se

# Chemical_IUPAC_Name:
[(2R)-2-amino-2-carboxyethane]selenonyl

# Chemical_Structure:
Not Available

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
Not Available

# Description:
Not Available

# Dosage_Forms:
Not Available

# Drug_Category:
Not Available

# Drug_Interactions:
Not Available

# Drug_Reference:
Not Available

# Drug_Type:
Experimental
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
Not Available

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
Not Available

# Food_Interactions:
Not Available

# GenBank_ID:
Not Available

# Generic_Name:
Dioxyselenocysteine

# HET_ID:
SOC

# Half_Life:
Not Available

# InChI_Identifier:
InChI=1S/C3H6NO4Se/c4-2(3(5)6)1-9(7)8/h2H,1,4H2,(H,5,6)/t2-/m0/s1

# InChI_Key:
InChIKey=CFDIKEIPXZDMLP-REOHCLBHSA-N

# Indication:
Not Available

# KEGG_Compound_ID:
Not Available

# KEGG_Drug_ID:
Not Available

# LIMS_Drug_ID:
2442

# Mechanism_Of_Action:
Not Available

# Melting_Point:
Not Available

# Molecular_Weight_Avg:
199.04

# Molecular_Weight_Mono:
199.946204513

# Organisms_Affected:
Not Available

# PDB_Experimental_ID:
1UBN

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
Not Available

# Pharmacology:
Not Available

# Predicted_LogP_Hydrophobicity:
-3.2

# Predicted_LogS:
0.03

# Predicted_Water_Solubility:
2.15e+02 g/l

# Primary_Accession_No:
DB02442

# Protein_Binding:
Not Available

# PubChem_Compound_ID:
17754171

# PubChem_Substance_ID:
46506335

# RxList_Link:
Not Available

# Salts:
Not Available

# Secondary_Accession_No:
EXPT02935

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
N[C@@H](C[Se](=O)=O)C(O)=O

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
Not Available

# Synthesis_Reference:
Not Available

# Toxicity:
Not Available

# Update_Date:
2013-02-08 16:21:08 -0700

# Wikipedia_Link:
Not Available

# pKa_Isoelectric_Point:
Not Available

# Drug_Target_1_Cellular_Location:
Secreted protein

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
Not Available

# Drug_Target_1_GenBank_ID_Gene:
K02496

# Drug_Target_1_GenBank_ID_Protein:
142526

# Drug_Target_1_GeneCard_ID:
Not Available

# Drug_Target_1_Gene_Name:
apr

# Drug_Target_1_Gene_Sequence:
>1149 bp
GTGAGAGGCAAAAAAGTATGGATCAGTTTGCTGTTTGCTTTAGCGTTAATCTTTACGATG
GCGTTCGGCAGCACATCCTCTGCCCAGGCGGCAGGGAAATCAAACGGGGAAAAGAAATAT
ATTGTCGGGTTTAAACAGACAATGAGCACGATGAGCGCCGCTAAGAAGAAAGATGTCATT
TCTGAAAAAGGCGGGAAAGTGCAAAAGCAATTCAAATATGTAGACGCAGCTTCAGCTACA
TTAAACGAAAAAGCTGTAAAAGAATTGAAAAAAGACCCGAGCGTCGCTTACGTTGAAGAA
GATCACGTAGCACATGCGTACGCGCAGTCCGTGCCTTACGGCGTATCACAAATTAAAGCC
CCTGCTCTGCACTCTCAAGGCTACACTGGATCAAATGTTAAAGTAGCGGTTATCGACAGC
GGTATCGATTCTTCTCATCCTGATTTAAAGGTAGCAGGCGGAGCCAGCATGGTTCCTTCT
GAAACAAATCCTTTCCAAGACAACAACTCTCACGGAACTCACGTTGCCGGCACAGTTGCG
GCTCTTAATAACTCAATCGGTGTATTAGGCGTTGCGCCAAGCGCATCACTTTACGCTGTA
AAAGTTCTCGGTGCTGACGGTTCCGGCCAATACAGCTGGATCATTAACGGAATCGAGTGG
GCGATCGCAAACAATATGGACGTTATTAACATGAGCCTCGGCGGACCTTCTGGTTCTGCT
GCTTTAAAAGCGGCAGTTGATAAAGCCGTTGCATCCGGCGTCGTAGTCGTTGCGGCAGCC
GGTAACGAAGGCACTTCCGGCAGCTCAAGCACAGTGGGCTACCCTGGTAAATACCCTTCT
GTCATTGCAGTAGGCGCTGTTGACAGCAGCAACCAAAGAGCATCTTTCTCAAGCGTAGGA
CCTGAGCTTGATGTCATGGCACCTGGCGTATCTATCCAAAGCACGCTTCCTGGAAACAAA
TACGGGGCGTACAACGGTACGTCAATGGCATCTCCGCACGTTGCCGGAGCGGCTGCTTTG
ATTCTTTCTAAGCACCCGAACTGGACAAACACTCAAGTCCGCAGCAGTTTAGAAAACACC
ACTACAAAACTTGGTGATTCTTTCTACTATGGAAAAGGGCTGATCAACGTACAGGCGGCA
GCTCAGTAA

# Drug_Target_1_General_Function:
Posttranslational modification, protein turnover, chaperones

# Drug_Target_1_General_References:
12524032	Peng Y, Huang Q, Zhang RH, Zhang YZ: Purification and characterization of a fibrinolytic enzyme produced by Bacillus amyloliquefaciens DC-4 screened from douchi, a traditional Chinese soybean food. Comp Biochem Physiol B Biochem Mol Biol. 2003 Jan;134(1):45-52.
2684274	Pantoliano MW, Whitlow M, Wood JF, Dodd SW, Hardman KD, Rollence ML, Bryan PN: Large increases in general stability for subtilisin BPN' through incremental changes in the free energy of unfolding. Biochemistry. 1989 Sep 5;28(18):7205-13.
4399039	Alden RA, Wright CS, Kraut J: A hydrogen-bond network at the active site of subtilisin BPN'. Philos Trans R Soc Lond B Biol Sci. 1970 Feb 12;257(813):119-24.
5249818	Markland FS, Shaw E, Smith EL: Identification of histidine 64 in the active site of subtilisin. Proc Natl Acad Sci U S A. 1968 Dec;61(4):1440-7.
6065094	Markland FS, Smith EL: Subtilisin BPN. VII. Isolation of cyanogen bromide peptides and the complete amino acid sequence. J Biol Chem. 1967 Nov 25;242(22):5198-211.
6090391	Vasantha N, Thompson LD, Rhodes C, Banner C, Nagle J, Filpula D: Genes for alkaline protease and neutral protease from Bacillus amyloliquefaciens contain a large open reading frame between the regions coding for signal sequence and mature protein. J Bacteriol. 1984 Sep;159(3):811-9.
6316278	Wells JA, Ferrari E, Henner DJ, Estell DA, Chen EY: Cloning, sequencing, and secretion of Bacillus amyloliquefaciens subtilisin in Bacillus subtilis. Nucleic Acids Res. 1983 Nov 25;11(22):7911-25.
6387152	Hirono S, Akagawa H, Mitsui Y, Iitaka Y: Crystal structure at 2.6 A resolution of the complex of subtilisin BPN' with streptomyces subtilisin inhibitor. J Mol Biol. 1984 Sep 15;178(2):389-414.

# Drug_Target_1_HGNC_ID:
Not Available

# Drug_Target_1_HPRD_ID:
Not Available

# Drug_Target_1_ID:
2517

# Drug_Target_1_Locus:
Not Available

# Drug_Target_1_Molecular_Weight:
39181

# Drug_Target_1_Name:
Subtilisin BPN'

# Drug_Target_1_Number_of_Residues:
382

# Drug_Target_1_PDB_ID:
1SUP

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
PF00082	Peptidase_S8
PF05922	Subtilisin_N

# Drug_Target_1_Protein_Sequence:
>Subtilisin BPN' precursor
MRGKKVWISLLFALALIFTMAFGSTSSAQAAGKSNGEKKYIVGFKQTMSTMSAAKKKDVI
SEKGGKVQKQFKYVDAASATLNEKAVKELKKDPSVAYVEEDHVAHAYAQSVPYGVSQIKA
PALHSQGYTGSNVKVAVIDSGIDSSHPDLKVAGGASMVPSETNPFQDNNSHGTHVAGTVA
ALNNSIGVLGVAPSASLYAVKVLGADGSGQYSWIINGIEWAIANNMDVINMSLGGPSGSA
ALKAAVDKAVASGVVVVAAAGNEGTSGSSSTVGYPGKYPSVIAVGAVDSSNQRASFSSVG
PELDVMAPGVSIQSTLPGNKYGAYNGTSMASPHVAGAAALILSKHPNWTNTQVRSSLENT
TTKLGDSFYYGKGLINVQAAAQ

# Drug_Target_1_Reaction:
Hydrolysis of proteins with broad specificity for peptide bonds, and a preference for a large uncharged residue in P1. Hydrolyses peptide amides

# Drug_Target_1_Signals:
1-32

# Drug_Target_1_Specific_Function:
Subtilisin is an extracellular alkaline serine protease, it catalyzes the hydrolysis of proteins and peptide amides. Has a high substrate specificity to fibrin

# Drug_Target_1_SwissProt_ID:
P00782

# Drug_Target_1_SwissProt_Name:
SUBT_BACAM

# Drug_Target_1_Synonyms:
Alkaline protease
EC 3.4.21.62
Subtilisin BPN' precursor
Subtilisin DFE
Subtilisin Novo

# Drug_Target_1_Theoretical_pI:
9.61

# Drug_Target_1_Transmembrane_Regions:
None

#END_DRUGCARD DB02442
